Who are JE-CV Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ChimeriVax™-JE, ChimeriVax-JE, Japanese Encephalitis vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/je-cv-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

JE-CV Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

JE-CV Vaccine (JE-CV Vaccine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated chimeric vaccine. Area: Infectious Disease / Immunology.

phase 3 Live attenuated chimeric vaccine Japanese encephalitis virus and dengue virus (serotypes 1-4) structural antigens Infectious Disease / Immunology Biologic Live · refreshed every 30 min

Target snapshot

JE-CV Vaccine (JE-CV Vaccine) — Sanofi Pasteur, a Sanofi Company. JE-CV is a chimeric vaccine that combines the live attenuated Japanese encephalitis virus backbone with dengue virus structural proteins to provide protection against both Japanese encephalitis and dengue viruses.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
JE-CV Vaccine TARGET	JE-CV Vaccine	Sanofi Pasteur, a Sanofi Company	phase 3	Live attenuated chimeric vaccine	Japanese encephalitis virus and dengue virus (serotypes 1-4) structural antigens
ChimeriVax™-JE	ChimeriVax™-JE	Sanofi	phase 3	Live attenuated chimeric vaccine
ChimeriVax-JE, Japanese Encephalitis vaccine	ChimeriVax-JE, Japanese Encephalitis vaccine	Sanofi	phase 3	Live attenuated chimeric vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated chimeric vaccine class)

Sanofi · 2 drugs in this class
Sanofi Pasteur, a Sanofi Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). JE-CV Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/je-cv-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab